• Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to FDA-approved seizure drug, Epidiolex
• The study will also compare DehydraTECH-CBD to generic CBD
• EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3 2022
• Lexaria received new patent awards in Mexico and Japan, strengthening its IP portfolio to 23 granted patents

Lexaria Bioscience (NASDAQ: LEXX), the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology, recently announced it had commenced an important new animal study, EPIL-A21-1 (https://ibn.fm/LG7O6).

EPIL-A21-1, which will be conducted by a talented team that includes respirology and neurology experts, will explore whether DehydraTECH-processed cannabidiol (“CBD”) evidences similar or superior efficacy in reducing or inhibiting seizure activity compared to Epidiolex, which is now sold by Jazz Pharmaceuticals (“Jazz”) subsequent to the 2021 US$7.2 billion takeover of GW Pharmaceuticals plc by Jazz. The study will also compare DehydraTECH-CBD to generic CBD.

With laboratory studies, research reports, and anecdotal evidence suggesting that CBD could potentially control seizures, and results from clinical trials involving Epidiolex – now the first FDA-approved CBD-based drug for the treatment of seizures associated with two rare and severe forms of pediatric epilepsy, Dravet syndrome and Lennox-Gastaut syndrome – indicating the advantageous effects of CBD in treating treatment-resistant seizure disorders, this non-psychoactive component of marijuana represents hope for patients who have been resistant to conventional anti-seizure drugs (https://ibn.fm/6NQ5E).

Through previous human and animal studies, Lexaria has evidenced that DehydraTECH improves the speed of onset is more effective at delivering CBD into the bloodstream, and increases brain absorption of CBD. Having already shown success with CBD, Lexaria believes the DehydraTECH technology could potentially improve therapeutic efficacy for a range of disease conditions affecting the central nervous system, including epilepsy, hence the EPIL-A21-1 study.

The study is being conducted by a leading US-based independent laboratory using advanced DehydraTECH 2.0 formulations and has entered early-stage preparatory work. Results are expected by Q3 2022.

Elsewhere, Lexaria, which as of September of 2021 had 21 issued patents and more than 50 pending patent applications globally (https://ibn.fm/i2Ku2), recently announced it had received its first patent award for DehydraTECH in Mexico and another in Japan. The patent award in Mexico safeguards the proprietary technology for use with cannabinoids and nicotine, while the patent in Japan is for the use of DehydraTECH with non-psychoactive cannabinoids, vitamins, nicotine, or non-steroidal anti-inflammatory (“NSAID”) substances.

These are two of the five patents that have been awarded to Lexaria in 2021.  The pair also strengthen the company’s IP portfolio with a collection that now includes 23 granted patents covering multiple countries.

Lexaria is a global leader in enhancing the speed and efficiency of orally-delivered fat-soluble APIs and drugs through its proprietary drug delivery technology, DehydraTECH. The technology pairs APIs with fatty acids such as long-chain fatty acid before applying the resulting combination to carrier particles like gum Arabic or sorbitol. The product then undergoes a dehydration synthesis procedure before being rendered for use in the desired final form factor.

Through this proprietary and revolutionary technology, Lexaria makes it possible to deliver bioactive substances via oral ingestion without the need for unhealthy, deleterious practices of inhalation dosing, as is the case with nicotine, and without the need for co-administration with harmful sugars or sweeteners commonly used to mask bitter tastes.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.